Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its price target lifted by investment analysts at Citigroup from GBX 1,700 to GBX 1,870 in a research report issued to clients and investors on Wednesday,Digital Look reports. The brokerage currently has a "buy" rating on the stock. Citigroup's price target points to a potential upside of 13.82% from the company's previous close.
Other equities research analysts also recently issued reports about the stock. Berenberg Bank boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Jefferies Financial Group lifted their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a "buy" rating in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of GBX 2,060.
Get Our Latest Research Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
HIK opened at GBX 1,643 on Wednesday. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a market cap of £3.43 billion, a price-to-earnings ratio of 9.08, a PEG ratio of 2.38 and a beta of 0.66. The company's fifty day moving average price is GBX 1,542.79 and its two-hundred day moving average price is GBX 1,454.39. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.
Insider Transactions at Hikma Pharmaceuticals
In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by company insiders.
About Hikma Pharmaceuticals
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
